Department of Social Work, Meiho University, Pingdung, Taiwan.
Division of Hematology and Oncology, Department of Internal Medicine, Hemophilia and Thrombosis Treatment Center, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, Lotung Poh-Ai Hospital, Yilan, Taiwan.
Sleep Med. 2022 Dec;100:254-261. doi: 10.1016/j.sleep.2022.08.014. Epub 2022 Sep 8.
Whether preexisting sleep disorder is an independent risk factor for cancer remains unclear. Therefore, we performed this propensity score-matched population-based cohort study to compare the incidence rate ratios (IRRs) of specific cancers between patients with and without sleep disorders.
Patients were categorized into two groups on the basis of the presence or absence of sleep disorders and matched at a 1:1 ratio.
Propensity score matching yielded a final cohort of 289,162 patients (i.e., 144,581 and 144,581 in the sleep disorder and nonsleep disorder groups, respectively) who were eligible for further analysis. In multivariate Cox regression analysis, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) of cancer risk in the sleep disorder group compared with the nonsleep disorder group was 1.07 (1.04-1.12; P = 0.0001). Furthermore, the adjusted IRRs (95% CIs) for all cancers, breast cancer, and ovarian cancer in the patients with sleep disorders were 1.08 (1.02-1.18), 1.20 (1.08-1.32), and 1.30 (1.10-1.52), respectively.
The results suggested that sleep disorders are a significant risk factor for all cancers, breast cancer, and ovarian cancer.
睡眠障碍是否为癌症的独立危险因素尚不清楚。因此,我们开展了这项倾向评分匹配的基于人群的队列研究,以比较睡眠障碍患者和无睡眠障碍患者特定癌症的发病率比值比(IRR)。
根据是否存在睡眠障碍将患者分为两组,并以 1:1 的比例进行匹配。
倾向评分匹配后得到了 289162 例符合进一步分析条件的患者(即睡眠障碍组和无睡眠障碍组各 144581 例)。多变量 Cox 回归分析显示,与无睡眠障碍组相比,睡眠障碍组的癌症风险调整后危险比(aHR;95%置信区间[CI])为 1.07(1.04-1.12;P=0.0001)。此外,睡眠障碍患者的所有癌症、乳腺癌和卵巢癌的调整后 IRR(95%CI)分别为 1.08(1.02-1.18)、1.20(1.08-1.32)和 1.30(1.10-1.52)。
结果提示睡眠障碍是所有癌症、乳腺癌和卵巢癌的重要危险因素。